163 related articles for article (PubMed ID: 26200283)
21. The case of double primary lung adenocarcinomas with an EGFR mutation and ALK translocation successfully treated with alectinib at the post-surgical recurrence.
Tsunezuka Y; Tanaka N; Fujimori H; Togashi Y; Baba S; Takeuchi K; Katayanagi K; Kurumaya H; Kitade H; Atagi S; Yano S
J Med Invest; 2017; 64(3.4):305-307. PubMed ID: 28955002
[TBL] [Abstract][Full Text] [Related]
22. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
[TBL] [Abstract][Full Text] [Related]
23. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
[TBL] [Abstract][Full Text] [Related]
25. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
[No Abstract] [Full Text] [Related]
26. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
Nagasaka M; Fisher A; Chowdhury T; Ge Y; Sukari A
Clin Lung Cancer; 2021 Jan; 22(1):e51-e53. PubMed ID: 32893122
[No Abstract] [Full Text] [Related]
27. Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy.
Grubb WR; Machtay M; Dowlati A; Biswas T
Pract Radiat Oncol; 2019 Mar; 9(2):e129-e133. PubMed ID: 30665865
[No Abstract] [Full Text] [Related]
28. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
[TBL] [Abstract][Full Text] [Related]
29. Alectinib Approved for ALK+ Lung Cancer.
Cancer Discov; 2016 Feb; 6(2):115. PubMed ID: 26739884
[TBL] [Abstract][Full Text] [Related]
30. A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.
Zhong JM; Zhang GF; Lin L; Li DY; Liu ZH
Lung Cancer; 2020 Jul; 145():211-212. PubMed ID: 32409002
[No Abstract] [Full Text] [Related]
31. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.
Sehgal K; Peters MLB; VanderLaan PA; Rangachari D; Kobayashi SS; Costa DB
J Thorac Oncol; 2019 Jan; 14(1):e1-e3. PubMed ID: 29981924
[No Abstract] [Full Text] [Related]
32. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.
Tsui DCC; Aisner D; Nijmeh H; Bao L; Menter A; Camidge DR
Clin Lung Cancer; 2022 Mar; 23(2):e99-e103. PubMed ID: 34330640
[No Abstract] [Full Text] [Related]
33. [Discovery and development of alectinib hydrochloride (ALECENSAR capsule 20 mg and 40 mg)
].
Yoshimura Y; Sakamoto H; Tanaka T; Inagaki N; Uzu M
Nihon Yakurigaku Zasshi; 2015 Jun; 145(6):318-24. PubMed ID: 26063155
[No Abstract] [Full Text] [Related]
34. ALK-Rearranged Squamous Cell Carcinoma of the Lung Treated with Two Lines of ALK Inhibitors.
Bolzacchini E; Tuzi A; Pinotti G
J Thorac Oncol; 2017 May; 12(5):e55-e57. PubMed ID: 28434517
[No Abstract] [Full Text] [Related]
35. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
[TBL] [Abstract][Full Text] [Related]
36. Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.
Nakasuka T; Ichihara E; Makimoto G; Maeda Y; Kiura K
J Thorac Oncol; 2019 Aug; 14(8):e168-e169. PubMed ID: 31345339
[No Abstract] [Full Text] [Related]
37. Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.
Robesova B; Bajerova M; Hausnerova J; Skrickova J; Tomiskova M; Dvorakova D
Lung Cancer; 2015 Mar; 87(3):318-20. PubMed ID: 25601488
[TBL] [Abstract][Full Text] [Related]
38. A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
[TBL] [Abstract][Full Text] [Related]
39. A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line.
Kodama T; Motoi N; Ninomiya H; Sakamoto H; Kitada K; Tsukaguchi T; Satoh Y; Nomura K; Nagano H; Ishii N; Terui Y; Hatake K; Ishikawa Y
J Thorac Oncol; 2014 Nov; 9(11):1638-46. PubMed ID: 25144242
[TBL] [Abstract][Full Text] [Related]
40. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
